NBI-6024 is an altered peptide ligand that is designed to cause an immune response which result in preservation of beta-cell function and endogenous insulin production.
Investigated for use/treatment in diabetes mellitus type 1 and pediatric indications.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.